Nike stock at $38.40 is a speculative turnaround, not a value bargain

Nike is interesting at $38.40, but the evidence supports a speculative comeback position, not a confident bargain call. For a patient investor, a small initial purchase is defensible. For someone who needs dependable income or dislikes uncertain recoveries, waiting is the stronger choice. The recovery model below becomes more attractive around $34, provided the business case survives.

Buying a famous brand after a fall feels like finding your favourite trainers in the clearance aisle. The temptation is immediate. The awkward question comes later: has the price fallen faster than the quality?

With Nike, you have to check the sole.

First, take the refund out of the running shoes

Nike’s latest quarter reported 49.2% gross margin and $0.72 earnings per share. However, a $986 million tariff-recovery benefit contributed roughly 9 percentage points to margin and $0.52 to EPS. The quarter ended 31 May 2026. (Nike’s fourth-quarter results, 30 June 2026)

Reported Q4 EPS

$0.72

Tariff recovery included

$0.52

Q4 EPS without that benefit

$0.20

Dollars per diluted share, Q4 FY2026. The second and third bars sum to the first; they are components, not three separate quarters. Source: Nike's 30 June results.

The refund is real. Nike’s annual filing says substantially all the remaining refund receivable was collected after year-end. But recovering a past cost does not establish that customers are buying more shoes at full price. (Nike’s 2026 Form 10-K, Note 1, filed 15 July)

For the full year, Nike reported $2.10 EPS; management put EPS excluding the recovery at $1.58. That changes the price-to-earnings ratio—the price you pay for each dollar of annual profit—from 18.3 times to 24.3 times. (Nike’s official earnings-call transcript, 30 June, page 8)

  $2.10  reported annual EPS
− $0.52  tariff recovery  $1.58  excluding recovery

 $38.40 ÷ $2.10 = 18.3×
 $38.40 ÷ $1.58 = 24.3×

The cheapness depends on which earnings you believe Nike can repeat.

The comeback has a pulse

The operating picture is mixed. In Q4, North America grew 3%, wholesale 1%, while Direct fell 9% and Greater China 17%, all excluding currency movements. Full-year group sales were $46.4 billion, essentially flat as reported. (Nike’s FY2026 results and divisional tables)

There is a plausible route out. Chief executive Elliott Hill says running has delivered 5 consecutive quarters of double-digit growth. The harder job is Sportswear and Jordan Streetwear: together they represent roughly half of revenue, and management expects them to decline in FY2027. New products from the reorganised teams arrive in spring 2027. (Nike’s official transcript, pages 2, 5 and 15)

Here is the optimistic chain of events: better performance shoes attract customers; retailers reorder what actually sells; fewer discounts restore profit on each pair; those profits spread across enough of the business to matter.

Every link is plausible. Every link still needs evidence.

Wholesale growth alone cannot settle it. Selling a box of shoes to a retailer and selling those shoes to a delighted customer are different milestones. If the second never happens, today’s shipment can become tomorrow’s clearance sale.

The other runners are still moving

The market is not waiting politely for Nike to tie its laces.

Sources: Nike’s 30 June results, Adidas’s Q2 results, 30 July, On’s Q2 results, 11 August, Deckers’ Q1 FY2027 results, 23 July.

This is a momentum comparison, not a market-share calculation. The periods, sizes and product mixes differ; Hoka’s figure also includes currency effects. Adidas’s footwear growth was only 1%, even as group sales surged. On’s shoe sales grew 18.9% at constant currency, a more direct sign of pressure in performance footwear. The respective company releases above provide those category figures.

There is encouraging outside evidence too. Circana measured 13% growth in both US running-shoe dollars and pairs sold in the first half of 2026. Sport-lifestyle footwear declined. (Circana’s US footwear report, 17 August)

That helps explain how Nike can improve in running while its overall business struggles. It also sets the challenge: moving towards a growing category is useful, but competitors get to do it too.

The dividend: nice cushioning, thin coverage

Nike declared $0.41 a share quarterly, an annualised $1.64, or 4.27% at our reference price. Future payments require future declarations. (Nike’s dividend announcement, 6 August 2026)

FY2024 free cash flow

$6.617bn

FY2025 free cash flow

$3.268bn

FY2026 free cash flow

$2.184bn

Fiscal years end 31 May. Author calculation: operating cash flow less additions to property, plant and equipment. Source: Nike's 2026 Form 10-K cash-flow statement.

FY2026 operating cash flow was $2.868 billion, capital spending $684 million and dividends paid $2.407 billion. So our free-cash-flow measure covered 91% of the dividend, leaving a $223 million gap. (Nike’s 10-K, cash-flow statement)

That is a warning light, not a dividend-cut prediction. Cash collection timing matters, including the subsequent tariff receipts. A single fiscal year is not a permanent spending limit.

Nike also had $9.027 billion of cash and short-term investments against $7.942 billion of borrowings: about $1.085 billion net cash before leases, including $2 billion of debt due within a year. Operating lease liabilities add roughly $3.1 billion. (Nike’s 10-K, balance sheet)

The balance sheet gives Nike time. It does not give shareholders a free pass on weak cash generation. If income is your main reason to own this stock, ask how the payment will be funded after the recovery receipts stop.

Three finishes for the same race

Instead of borrowing an analyst’s price target, build the business that would justify the price. The following are our illustrative FY2029 scenarios, valued around September 2029. They are not Nike guidance, consensus estimates or probability-weighted forecasts.

All three assume 1.48 billion diluted shares, 22% tax, and zero net interest or other non-operating income. EPS equals revenue × operating margin × 78% ÷ shares. Price equals EPS × the assumed P/E. Operating margin means the share of revenue left after product and operating costs, before interest and tax.

The bear case is a stalled recovery; base is a partial recovery; bull is a strong comeback.

Revenue, margin and EPS refer to FY2029. Returns start at $38.40; total return includes the assumed dividend payout. The annualised equivalent is explained below.

Stalled recovery · FY2029

$22.26

Reference close · 4 Sep 2026

$38.40

Partial recovery · FY2029

$46.48

Strong comeback · FY2029

$81.96

Illustrative author valuations, not a price forecast or trading range. Bar lengths start at zero. Future prices exclude dividends; return calculations above include the stated dividend assumptions.

The base case needs only modest sales growth from today’s annual revenue, but 9% operating margin is a recovery assumption, not a fact about the next quarter. The bull case needs both a stronger business and investors willing to pay a higher multiple. The bear case assumes an immediate 50% dividend reduction; that is a stress assumption, not an announced cut.

A stock can disappoint twice: the earnings recover less than expected, then the market pays less for each dollar of them. On base-case earnings, using 16× instead of 20× produces a price of about $37.19. Better operations would then leave the share price close to where it started.

Why the entry price changes the answer

The base case ends with about $51.40 per starting share: a $46.48 stock plus $4.92 of accumulated dividends. At $38.40, that is roughly 10.2% annualised. Whether that is enough depends on the extra return you demand for an uncertain single-company recovery.

Using 15% a year as an explicitly chosen hurdle—not a promised return—gives this entry price:

 $46.48  future share price
+ $4.92  3 years of dividends $51.40  ending wealth

 $51.40 ÷ 1.15³ ≈ $33.80

≈$34

A 12% hurdle allows roughly $36.59. These calculations make the trade-off visible: paying less gives the same recovery more room to disappoint. If recovery takes 5 years instead of 3, the base terminal price and an unchanged dividend yield only about 7.3% annualised from $38.40. Patience has an opportunity cost.

At $38.40: suitable for consideration as a small speculative holding, with a willingness to sit through poor quarters. Around $34: a stronger entry under this model, if the evidence has not deteriorated. For a conservative income investor: wait for better cash coverage and operating confirmation. A diversified holding is the benchmark for the concentration risk you are taking, even though its future return is also unknown.

Buying in stages can reduce the risk of choosing one unfortunate day. It cannot turn a declining business into a good investment. Reassess after results before adding just because the price fell.

The next lap: what would change the verdict

Management’s outlook calls for low-to-mid-single-digit sales declines cumulatively across Q4 FY2026 through Q2 FY2027, and slightly positive gross-margin growth in Q1. That is not full-year FY2027 guidance. (Nike’s official transcript, pages 10–11)

21 September: Nike leaves the S&P 100. The announcement does not remove it from the S&P 500. Rebalancing may affect trading flows; it does not tell you the value of the next pair of shoes sold. (S&P Dow Jones Indices’ rebalance announcement, 4 September)

1 October, after the US close: Nike reports Q1 FY2027. That is the next scheduled financial checkpoint for this thesis. (Nike’s earnings announcement, 28 August)

There is a cost to waiting: a convincing result could lift the price before you buy. There is also a benefit: you pay with a little potential upside to learn whether the recovery is arriving. For a cautious investor, that is a reasonable exchange.

What this analysis cannot settle

Public results cannot prove that the next product cycle will restore Nike’s pricing power. Management’s category claims are attributed, not independently audited here. Competitor results use different reporting periods and mixes. This model does not forecast new tariff measures, buybacks, dilution, acquisitions, exchange rates or the timing of a potential dividend change. If you invest in euros, dollar movements change your realised return as well.

The scenario prices are conditional examples. They do not assign probabilities, identify a market bottom or cap the loss. Before acting, refresh the price and check for disclosures after 7 September.

The decision: Nike has enough going for it to merit a watchlist and, for someone comfortable with turnaround risk, a small starting position. At the reference price, the upside still asks you to trust a recovery. Near $34, the same assumptions offer better compensation for that trust. The next earnings report should help you decide how much trust has been earned.

Educational investment analysis, not personalised financial advice. The scenarios are hypothetical; they are not an instruction to take any position.